Lung Bioengineering has acquired the XPS™ for use in its new Jacksonville EVLP center

Report this content

Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), has purchased an XVIVO Perfusion System (XPS™) with STEEN Solution™ Perfusate to use in its new ex vivo lung perfusion (EVLP) center in Jacksonville, Florida. Lung Bioengineering previously purchased an XPS™ to use in its EVLP center in Silver Spring, Maryland in 2018. The aim of the new EVLP center in Jacksonville is to reduce the shortage of transplantable lungs through the use of a centralized organ evaluation service.

Lung Bioengineering purchased an XVIVO Perfusion System (XPS™) with STEEN Solution Perfusate from XVIVO Perfusion AB (STO: XVIVO) for use in its Jacksonville Ex Vivo Lung Perfusion (EVLP) center. XVIVO Perfusion will continue to provide training and supplies for use of their machines by transplant hospitals to re-evaluate donated lungs that have initially been deemed unsuitable for transplant. Lung Bioengineering and XVIVO Perfusion will also continue to cooperate and collaborate in promoting the use of centralized XPS EVLP services that could increase the supply of transplantable lungs to address needless patient deaths on the transplant waitlist.

On April 26, 2019 XVIVO received Premarket approval (PMA) from the FDA for XPS with STEEN Solution Perfusate for sale on the American market. The XPS with STEEN Solution Perfusate was the first medical device that was approved for EVLP of initially unacceptable donated lungs.

“We are very pleased that the collaboration agreement is extended to Lung Bioengineering´s new Jacksonville facility. United Therapeutics’ impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages,” said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.

August 23, 2019
Magnus Nilsson
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159,
Magnus Nilsson, CEO, +46 31 788 2150,

For further information on XVIVO Perfusion’s business, please refer to the company’s website,

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 am CET on August 23, 2019.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website: